NasdaqGS - Nasdaq Real Time Price USD

Ovid Therapeutics Inc. (OVID)

Compare
0.9991 -0.0209 (-2.05%)
At close: December 20 at 4:00:01 PM EST
0.9921 -0.01 (-0.70%)
After hours: December 20 at 4:15:01 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
631.6950
391.6950
1,502.7480
208,382.7790
12,617.2210
Operating Expense
69,983.8840
59,673.8840
57,050.3990
84,172.5830
94,048.3940
Operating Income
-69,352.1890
-59,282.1890
-55,547.6510
124,210.1960
-81,431.1730
Net Non Operating Interest Income Expense
--
4,900.0000
--
--
--
Other Income Expense
31,907.0000
2,000.0000
1,379.1320
-45.6900
395.4010
Pretax Income
-32,501.9590
-52,338.9590
-54,169.0290
124,163.4020
-81,035.5760
Tax Provision
--
--
--
1,328.8180
--
Net Income Common Stockholders
-32,501.9590
-52,338.9590
-54,169.0290
119,837.2400
-81,035.5760
Diluted NI Available to Com Stockholders
-32,501.9590
-52,338.9590
-54,169.0290
119,837.2400
-81,035.5760
Basic EPS
-0.46
-0.74
-0.77
1.78
-1.39
Diluted EPS
-0.46
-0.74
-0.77
1.76
-1.39
Basic Average Shares
70,824.8670
70,580.6040
70,424.8190
67,479.4030
58,451.2930
Diluted Average Shares
70,824.8670
70,580.6040
70,424.8190
68,067.9920
58,451.2930
Total Operating Income as Reported
-69,351.4640
-59,281.4640
-55,548.1610
124,209.0920
-81,430.9770
Total Expenses
69,983.8840
59,673.8840
57,050.3990
84,172.5830
94,048.3940
Net Income from Continuing & Discontinued Operation
-32,501.9590
-52,338.9590
-54,169.0290
122,834.5840
-81,035.5760
Normalized Income
-34,501.9590
-54,338.9590
-54,169.0290
122,834.5840
-81,035.5760
Interest Income
--
4,900.0000
--
--
--
Net Interest Income
--
4,900.0000
--
--
--
EBIT
-69,352.1890
-59,282.1890
-55,547.6510
124,210.1960
-81,431.1730
EBITDA
-67,730.6140
-57,685.6140
-54,166.0450
124,447.2750
-81,124.3250
Reconciled Depreciation
1,621.5750
1,596.5750
1,381.6060
237.0790
306.8480
Net Income from Continuing Operation Net Minority Interest
-32,501.9590
-52,338.9590
-54,169.0290
122,834.5840
-81,035.5760
Total Unusual Items Excluding Goodwill
2,000.0000
2,000.0000
--
--
--
Total Unusual Items
2,000.0000
2,000.0000
--
--
--
Normalized EBITDA
-69,730.6140
-59,685.6140
-54,166.0450
124,447.2750
-81,124.3250
Tax Rate for Calcs
--
--
--
0.0000
--
12/31/2020 - 5/5/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LXEO Lexeo Therapeutics, Inc.
6.28
+3.97%
 
SKYE Skye Bioscience, Inc.
2.7000
-5.59%
 
RYTM Rhythm Pharmaceuticals, Inc.
56.12
+1.15%
 
SPRB Spruce Biosciences, Inc.
0.4000
+4.68%
 
PRAX Praxis Precision Medicines, Inc.
76.52
+5.05%
 
CMPX Compass Therapeutics, Inc.
1.3800
+0.73%
 
STOK Stoke Therapeutics, Inc.
11.68
+3.36%
 
SLNO Soleno Therapeutics, Inc.
45.18
-0.04%
 
CRGX CARGO Therapeutics, Inc.
14.90
+10.29%
 
GLPG Galapagos NV
26.76
+1.48%